search
Back to results

Phoenix Thera-Lase for Treating Chronic Pain in Patients Taking Opioid on a PRN Basis

Primary Purpose

Pain

Status
Unknown status
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Low level 1 Watt
Phoenix Thera-Lase System 42
Phoenix Thera-Lase System 74
Sponsored by
Phoenix Thera-lase Systems, LLC
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Pain focused on measuring Pain, Low level laser therapy, Sham, Chronic Pain, Opioid, Physical activity, Quality of sleep

Eligibility Criteria

25 Years - 65 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Male or female patients
  • 25-65 years of age
  • taking oral opiate-containing analgesic medication on a PRN
  • patient with chronic pain related to an accident, injury or major surgery occurring within the past three years
  • Patients with a potentially treatable pain condition
  • Patient wiling to complete a daily diary for recording their pain score, activity level, quality of sleep and all pain-related medications for the three-week study period

Exclusion Criteria:

  • Use of any opioid-containing pain medications for more than three years
  • History of alcohol or drug abuse, or drug-seeking behavior
  • Previous treatment for drug abuse in detox center or hospital
  • Current psychiatric condition which require centrally- active medications
  • Current excessive use of alcohol
  • Any unstable medical conditions (e.g. coronary artery disease, hepato-renal or pulmonary disease)
  • Patients not capable of consenting for themselves
  • Pregnant women
  • Women of child bearing potential not using acceptable birth control methods.

Sites / Locations

  • Phoenix Thera-Lase SystemsRecruiting

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

Active Comparator

Experimental

Experimental

Arm Label

Low level 1 Watt

Phoenix Thera-Lase System 42

Phoenix Thera-Lase System 74

Arm Description

The Phoenix Thera-Lase System will be on 1 watt while retaining appropriate "blinding" of both the operator and the patient. Treatments will be applied to the primary area of the body associated with pain for which analgesic (pain) medication is currently required. Each treatment session will last for 20-40 minutes.

The Phoenix Thera-Lase System will be on 42 watts while retaining appropriate "blinding" of both the operator and the patient. Treatments will be applied to the primary area of the body associated with pain for which analgesic (pain) medication is currently required. Each treatment session will last for 20-40 minutes.

The Phoenix Thera-Lase System will be on 74 watts while retaining appropriate "blinding" of both the operator and the patient. Treatments will be applied to the primary area of the body associated with pain for which analgesic (pain) medication is currently required. Each treatment session will last for 20-40 minutes.

Outcomes

Primary Outcome Measures

Reduce chronic pain
reduce of opioid analgesic dosage.

Secondary Outcome Measures

Level of physical activity
It will be assessed with a questionnaire
Quality of sleep
It will be assessed with a questionnaire

Full Information

First Posted
November 10, 2016
Last Updated
February 17, 2017
Sponsor
Phoenix Thera-lase Systems, LLC
search

1. Study Identification

Unique Protocol Identification Number
NCT02964000
Brief Title
Phoenix Thera-Lase for Treating Chronic Pain in Patients Taking Opioid on a PRN Basis
Official Title
Adjunct Use of the Phoenix Thera-Lase for Treating Chronic Pain in Patients Taking Opioid-containing Medication on a PRN Basis
Study Type
Interventional

2. Study Status

Record Verification Date
February 2017
Overall Recruitment Status
Unknown status
Study Start Date
November 2016 (undefined)
Primary Completion Date
December 2017 (Anticipated)
Study Completion Date
December 2017 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Phoenix Thera-lase Systems, LLC

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
Hypothesis: Use of high level vs low level cold laser treatments will reduce chronic pain and the need for PRN opioid-containing analgesic medications. Secondary Hypothesis: High level (vs low level) laser treatments will increase the patients level of physical activity and quality of sleep.
Detailed Description
Previous studies with low level laser therapy have reported beneficial effects on the level of pain in patients with a variety of chronic pain conditions. We designed this controlled, double blind, randomized study to determine in the active laser group would have a reduction in the need for 'PRN pain medication'. Screening Testing Urine-toxicology screen. Assessment of level of activity and range of motion and functional capacity evaluation for upper and/ or lower extremity. Current drug history and use of analgesic medications including both opioid and or non-opioid analgesic medications. Drug history and current medications along with non-traditional alternative treatments such as (e.g. acupuncture, massage, herbal treatments, etc.) Protocol Outline After obtaining written informed consent, patients will be asked to complete all the pre-screening and "entry" questionnaires (e.g., SF-36). 11- point Verbal Rating Scale (VRS) for pain at rest and with physical activity (0= none to 10= severe), level of physical activity (0=inactive to 10= fully active), and quality of sleep (0=poor to 10=excellent). Current analgesic [pain] medications both daily and PRN medications. Randomized into active (Phoenix Thera-Lase [ PTL]) or "Low level" PTL group using a computer generated random numbers table. Treatment Sessions After obtaining written informed consent for participating in the study and signing the standard HIPPA forms, the patient will be asked to describe the location of their current pain symptoms. Pre-treatment baseline assessments VRS for pain at rest and with physical activity (e.g. walking, climbing stairs) Kinesiology functional capacity evaluation (FCE) for upper and/ or lower extremities or low back (depending on location of pain). Current opioid and non-opioid analgesic medication usage Clinical opioid withdrawal scale (COWS) at baseline (the COWS will be repeated at the end of the 1st, 2nd, and 3rd week of treatments). Treatment sessions - Active or low level therapy for 20 - 40 min on Monday, Wednesday, and Friday for 3 weeks. Post- treatment sessions VRS for pain at rest and with ambulation immediately after each treatment After the end of 3-week treatment period Repeat pre-screening questionnaires. Kinesiology functional capacity evaluation (FCE) for upper and/ or lower extremities or low back (depending on location of pain). Long-term Follow Up 30-days after the last treatment session, a standardized follow-up questionnaire will be administered.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Pain
Keywords
Pain, Low level laser therapy, Sham, Chronic Pain, Opioid, Physical activity, Quality of sleep

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Factorial Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
75 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Low level 1 Watt
Arm Type
Active Comparator
Arm Description
The Phoenix Thera-Lase System will be on 1 watt while retaining appropriate "blinding" of both the operator and the patient. Treatments will be applied to the primary area of the body associated with pain for which analgesic (pain) medication is currently required. Each treatment session will last for 20-40 minutes.
Arm Title
Phoenix Thera-Lase System 42
Arm Type
Experimental
Arm Description
The Phoenix Thera-Lase System will be on 42 watts while retaining appropriate "blinding" of both the operator and the patient. Treatments will be applied to the primary area of the body associated with pain for which analgesic (pain) medication is currently required. Each treatment session will last for 20-40 minutes.
Arm Title
Phoenix Thera-Lase System 74
Arm Type
Experimental
Arm Description
The Phoenix Thera-Lase System will be on 74 watts while retaining appropriate "blinding" of both the operator and the patient. Treatments will be applied to the primary area of the body associated with pain for which analgesic (pain) medication is currently required. Each treatment session will last for 20-40 minutes.
Intervention Type
Device
Intervention Name(s)
Low level 1 Watt
Other Intervention Name(s)
1 watt
Intervention Description
The Phoenix Thera-Lase System will be on 1 watt
Intervention Type
Device
Intervention Name(s)
Phoenix Thera-Lase System 42
Other Intervention Name(s)
42 Watts
Intervention Description
The Phoenix Thera-Lase System will be on 42 watts
Intervention Type
Device
Intervention Name(s)
Phoenix Thera-Lase System 74
Other Intervention Name(s)
74 Watts
Intervention Description
The Phoenix Thera-Lase System will be on 74 watts
Primary Outcome Measure Information:
Title
Reduce chronic pain
Time Frame
1 month
Title
reduce of opioid analgesic dosage.
Time Frame
one month
Secondary Outcome Measure Information:
Title
Level of physical activity
Description
It will be assessed with a questionnaire
Time Frame
1 month
Title
Quality of sleep
Description
It will be assessed with a questionnaire
Time Frame
one month

10. Eligibility

Sex
All
Minimum Age & Unit of Time
25 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Male or female patients 25-65 years of age taking oral opiate-containing analgesic medication on a PRN patient with chronic pain related to an accident, injury or major surgery occurring within the past three years Patients with a potentially treatable pain condition Patient wiling to complete a daily diary for recording their pain score, activity level, quality of sleep and all pain-related medications for the three-week study period Exclusion Criteria: Use of any opioid-containing pain medications for more than three years History of alcohol or drug abuse, or drug-seeking behavior Previous treatment for drug abuse in detox center or hospital Current psychiatric condition which require centrally- active medications Current excessive use of alcohol Any unstable medical conditions (e.g. coronary artery disease, hepato-renal or pulmonary disease) Patients not capable of consenting for themselves Pregnant women Women of child bearing potential not using acceptable birth control methods.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Paul F White, PhD, MD
Phone
214-770-3775
Email
paul.white@cshs.org
First Name & Middle Initial & Last Name or Official Title & Degree
Ofelia Loani Elvir Lazo, MD
Phone
310-721-0590
Email
loanidoc@yahoo.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Paul F White, PhD, MD
Organizational Affiliation
Phoenix Thera-Lase Systems
Official's Role
Principal Investigator
Facility Information:
Facility Name
Phoenix Thera-Lase Systems
City
Dallas
State/Province
Texas
ZIP/Postal Code
75231
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Paul F White, PhD, MD
Phone
214-770-3775
Email
paul.white@cshs.org

12. IPD Sharing Statement

Plan to Share IPD
Yes

Learn more about this trial

Phoenix Thera-Lase for Treating Chronic Pain in Patients Taking Opioid on a PRN Basis

We'll reach out to this number within 24 hrs